---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-013989"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:55:06.610799+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Genprex granted Israel patent for Reqorsa gene therapy with PD-1 antibodies

## Summary
- Israel Patent Office granted patent covering Reqorsa (quaratusugene ozeplasmid) in combination with PD-1 antibodies for cancer treatment.
- Patent expands IP portfolio previously granted in U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore, and Europe.
- Reqorsa is initially being developed for lung cancer; preclinical data shows complementarity with targeted drugs and immunotherapies.
- Israel lung cancer cases rose 33% in a decade; 200 new cases/month; leading cancer death cause in 2021.

## SEC filing metadata
- accession: 0001437749-26-013989
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926013989/0001437749-26-013989-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926013989/gnpx20260429_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-013989
- JSON: https://secwatch.observer/filing/0001437749-26-013989.json
- Plain text: https://secwatch.observer/filing/0001437749-26-013989.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.